Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Medline, boosting the price target to $53.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Rhyee has given his Buy rating due to a combination of factors, including his view that Medline’s 2026 guidance is set conservatively and leaves room for outperformance. He projects 2026 adjusted EBITDA of about $3.57 billion, already above management’s range, even after incorporating roughly $200 million of expected tariff pressure.
Rhyee also highlights solid segment fundamentals, with modest but resilient growth in the Medical Businesses and double‑digit adjusted EBITDA expansion in the SCS segment, supported by strong 2025 contract wins. Looking further ahead, he forecasts adjusted EBITDA rising to about $3.88 billion in 2027 and, using a DCF framework that values the shares at roughly 21x his 2027 estimate, he raises his price target to $53, reinforcing the Buy recommendation.
In another report released on February 27, TipRanks – Google also initiated coverage with a Buy rating on the stock with a $56.00 price target.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MDLN in relation to earlier this year.